期刊文献+

Expression of mir-34c-5p and mir-150-5pin nasopharyngeal carcinoma and up-regulated expression after invasion and apoptosis of nasopharyngeal carcinoma cells

下载PDF
导出
摘要 Objective MiRNAs are closely related to tumors,and we hypothesized there is specific miR expression in nasopharyngeal carcinoma(NPC).We intended to investigate the expression of mir-34c-5p and mir-150-5p in NPC and to investigate the effects of mir-34c-5p and mir-150-5p on apoptosis and invasion following up-regulated expression in HNE1 NPC cells.Methods MiR-34c-5p and miR-150-5p expression levels in 30 individual cases of NPC and nasopharyngitis were detected with gene chip and qRT-PCR techniques.miR-34c-5p and miR-150-5p were transfected into the NPC cell line HNE1 via liposomes.Their expression levels were detected with qRT-PCR,apoptosis was evaluated by flow cytometry,and invasion ability was assessed via Transwell migration assay.Results MiR-150-5p expression levels in NPC and nasopharyngitis were 0.165±0.092 and 1.062±0.280 respectively,and miR-34c-5p expression levels in NPC and nasopharyngitis were 0.417±0.220 and 1.385±0.739,respectively,which indicated miR-34c-5p and miR-150-5p were weakly expressed in NPC.Apoptosis rates in HNE1 cells transfected by miR-34c-5p and miR-150-5p were increased,by 12.7%and 7.6%,respectively,which were significantly higher compared to blank control(3.9%).The Transwell assay demonstrated that invasive HNE1 cell counts were 32.00±2.00 and 28.33±2.08,respectively,compared to 60.66±8.50 in the blank control(P<0.001).Conclusion MiR-34c-5p and miR-150-5p are lowly expressed in NPC,and their down-regulation may be associated with NPC.
出处 《Oncology and Translational Medicine》 CAS 2021年第1期25-30,共6页 肿瘤学与转化医学(英文版)
基金 Supported by grants from the National Natural Science foundation of China(No.81373698) Joint Special Scientific Research Project of the Department of Science and Technology of Guangdong Province-Guangdong Provincial Academy of Chinese Medical Sciences(No.2017A020213020) Zhongshan Key Scientific and Technological Project(No.2015B1003,2019B1096)。
  • 相关文献

参考文献2

二级参考文献17

  • 1Yoshizaki T, Ito M, Murono S, et al. Current understanding and man- agement of nasopharyngeal carcinoma [J]. Auris Nasus Larynx, 2012, 39 (2): 137-144. doi: 10.1016/j.anl.2011.02.012.
  • 2Xu T, Tang J, Gu M, et al. Recurrent nasopharyngeal carcinoma: a clinical dilemma and challenge [J]. Curr Oneol, 2013, 20(5):e406- e419. doi: 10.3747/co.20.1456.
  • 3Misso G, Di Martino MT, De Rosa G, et al. Mir-34: a new weapon against cancer[J]? Mol Ther Nucleic Acids, 2014, 3:e194. doi: 10.1038/mtna.2014.47.
  • 4Luo Z, Zhang L, Li Z, et al. An in silico analysis of dynamic chang- es in mieroRNA expression profiles in stepwise development of na- sopharyngeal carcinoma [J]. BMC Med Genomics, 2012, 5:3. doi: 10.1186/1755-8794-5-3.
  • 5Hagman Z, Haflidadottir BS, Ansari M, et al. The tumour suppres- sor miR-34c targets MET in prostate cancer cells [J]. Br J Cancer, 2013, 109(5):1271-1278. doi: 10.1038/bjc.2013.449.
  • 6Yang S, Li WS, Dong F, et al. KITLG is a novel target of miR-34c that is associated with the inhibition of growth and in,~asion in colorectal cancer cells [J]. J Cell Mol Med, 2014, 18(10):2092- 2102. doi: 10.1 l 11/jcmm.12368.
  • 7Xu M, Jin H, Xu CX, et al. MiR-34c inhibits osteosarcoma metasta- sis and chemoresistance [J]. Med Oncol, 2014, 31(6):972. doi: 10.1007/s 12032-014-0972-x.
  • 8Catuogno S, Cerchia L, Romano G, et al. miR-34c may protect lung cancer ceils from paclitaxel-induced apoptosis [J]. Oncogene, 2013, 32(3):341-351. doi: 10.1038/onc.2012.51.
  • 9Tong JH, Ng DC, Chau SL, et al. Putative tumour-suppressor gene DAB2 is frequently down regulated by promoter hypermethylation in nasopharyngeal carcinoma [J]. BMC Cancer, 2010, 10:253. doi: 10.1186/1471-2407-10-253.
  • 10Ebner OA, Selbach M. Quantitative proteomic analysis of gene regu- lation by miR-34a and miR-34c [J]. PLoS One, 2014, 9(3):e92166. doi: 10.1371/journal.pone.0092166.

共引文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部